No apparent pharmacokinetic interactions were found between henagliflozin: A novel sodium‐glucose co‐transporter 2 inhibitor and glimepiride in healthy Chinese male subjects.

What is known and objective: Henagliflozin is a novel selective sodium‐glucose co‐transporter 2 (SGLT2) inhibitor with similar inhibitory effect to ertugliflozin. Glimepiride is widely used to treat type 2 diabetes mellitus (T2DM) with few cardiovascular side effects. In the present study, we aimed...

Descripción completa

Detalles Bibliográficos

Publicado en:	Journal of Clinical Pharmacy & Therapeutics Vol. 47; no. 8; pp. 1225 - 1232
Autores principales:	Que, Linling, Huang, Kai, Xiang, Xuemei, Ding, Ying, Chu, Nannan, He, Qing
Formato:	research tables/charts Journal Article
Publicado:	Wiley-Blackwell Aug2022
Acceso en línea:	Ver este registro en EBSCOhost